In our third annual report on 10 exciting cancer drugs, there are plenty of R&D programs zipping through trials with the blessing of the FDA, which has awarded "breakthrough" status for expedited development to treatments in oncology more than any other field. Read the report >>
AMRI has locked down another 5-year partnership with Japan's Ono Pharmaceutical, agreeing to provide development and manufacturing services for the company's treatments, which include a promising multiple sclerosis drug.
An oral MS drug was credited with eliminating a large percentage of the brain lesions characteristic of the disease.
If at first you don't succeed with a blockbuster drug, try, try again. Merck KGaA 's Serono division has worked out a pair of new deals that will bring its R&D division in league with the
South San Francisco-based KAI Pharmaceuticals has inked a Japanese development and marketing deal for its lead therapy, nabbing a $13 million upfront payment from Ono Pharmaceutical. Now nearing the
Onyx's $851 million deal to buy out Proteolix and its potential blockbuster cancer drug is returning some handsome rewards this morning. Ono Pharmaceutical snagged the Japanese rights to the